PROTOONCOGENE MDM2 SNP309 (rs2279744) ANALYSIS
OF POLYMORPHISM IN THYROID CANCER: PAKISTANI POPULATION

M.S. IQBAL, I. MEHBOOB, S. KHALIQ, N. SARDAR, Sh. SHERZADA, Q. ALI

MDM2 has been found to be a major adverse regulatory factor for p 53 and to be associated with increased expression of MDM2 with the substantially earliest onset age of some tumors, including thyroid cancer, with single nucleotide polymorphism (SNP) in the SNP309 promoter region of MDM2. The purpose of this study was to evaluate the association between thyroid risk and polymorphism of MDM2 SNP309 in Pakistani people. We performed case-control work to test this relationship. The power of the association was measured by odds ratios and confidence intervals (CIs) of 95 %. For the codominant model, dominant model and recessive model, the ORs were performed together, respectively. The case-control investigation was conducted with 120 cases of thyroid and 70 controls. The risk of MDM2 SNP309 multiplied with the thyroid risk (GG vs. TT; OR = 1.54; 95 % CI = 1.04–2.29; and GG vs. GT/TT, OR = 1.42, 95 % CI = 1.30–1.72) had been significantly increased. The findings indicate that polymorphism MDM2 SNP309 is a low penetration risk factors for the development of men’s thyroid cancer.

Key words: Murine Double Minute 2(MDM2), polymor-phism, Pakistani population

Tsitologiya i Genetika 2022, vol. 56, no. 4, pp. 87-88

1. Department of Biotechnology, School of Applied Biology, University of Okara, Pakistan
2. Department of Biotechnology, Virtual University of Pakistan
3. University of Health Sciences Lahore, Pakistan
4. Department of Molecular Biology, School of Applied Biology, University of Okara, Pakistan
5. Department of Fisheries and Aquaculture, University of Veterinary and Animal Sciences, Lahore, 54000, Pakistan
6. Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan

E-mail: saim1692 gamil.com, sarfaraz2250 gmail.com

M.S. IQBAL, I. MEHBOOB, S. KHALIQ, N. SARDAR, Sh. SHERZADA, Q. ALI PROTOONCOGENE MDM2 SNP309 (rs2279744) ANALYSIS
OF POLYMORPHISM IN THYROID CANCER: PAKISTANI POPULATION, Tsitol Genet., 2022, vol. 56, no. 4, pp. 87-88.

In "Cytology and Genetics":
Muhammad Sarfaraz Iqbal, Iram Mehboob, Saba Khaliq, Nimra Sardar, Shahid Sherzada & Qurban Ali Protooncogene MDM2 SNP309 (rs2279744) Analysis of Polymorphism in Thyroid Cancer: Pakistani Population, Cytol Genet., 2022, vol. 56, no. 4, pp. 391–397
DOI: 10.3103/S0095452722040090

References

Ashfaq, F., Ali, Q., Haider, M., Hafeez, M., and Malik, A., Therapeutic activities of garlic constituent phytochemicals, Biol. Clin. Sci. Res. J., 2021, vol. 2021, no. 1, p. 53.

Cahilly-Snyder, L., Yang-Feng, T., Francke, U., and George, D.L., Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line, Somat. Cell Mol. Genet., 1987, vol. 13, pp. 235–244.

Cao, J., Zhang, M., Zhang, L., Lou, J., Zhou, F., and Fang, M., Non-coding RNA in thyroid cancer. Functions and mechanisms, Cancer Lett., 2021, vol. 496, pp. 117–226.

Chen, Y., Hao, Q., Wang, S., Cao, M., Huang, Y., Weng, X., Wang, J., Zhang, Z., He, X., Lu, H., and Zhou, X., Inactivation of the tumor suppressor p53 by long noncoding RNA RMRP, Proc. Natl. Acad. Sci. U. S. A., 2021, vol. 118, no. 29.

Fåhraeus, R. and Olivares-Illana, V., MDM2’s social network, Oncogene, 2014, vol. 33, pp. 4365–4376.

Fakharzadeh, S.S., Trusko, S.P., and George, D.L., Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line, EMBO J., 1991, vol. 10, pp. 1565–1569.

Humpton, T.J., Nomura, K., Weber, J., Magnussen, H.M., Hock, A.K., Nixon, C., Dhayade, S., Stevenson, D., Huang, D.T., Strathdee, D., and Blyth, K., Differential requirements for MDM2 E3 activity during embryogenesis and in adult mice, Genes Dev., 2021, vol. 35, nos. 1–2, pp. 117–132.

Jemal, A., Desantis, C., and Ward, E.M., Global patterns of cancer incidence and mortality rates and trends, Cancer Epid. Biomarkers Prev., 2010, vol. 19, pp. 1893–1908.

Levine, A.J., p53, the cellular gatekeeper for growth and division, Cell, 1997, vol. 88, pp. 323–331.

Malik, A., Hafeez, K., Nazar, W., Naeem, M., Ali, I., Ali, Q., Mujtaba, Z., Rana, M.A., and Hafeez, M.M., Assessment of controversial risk factors in development of breast cancer: a study from local population, Biol. Clin. Sci. Res. J., 2021, vol. 2021, no. 1, p. 49.

Momand, J., Jung, D., Wilczynski, S., and Niland, J., The MDM2 gene amplification database, Nucleic Acids Res., 1998, vol. 26, pp. 3453–3459.

Montes de Oca Luna, R., Wagner, D.S., and Lozano, G., Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53, Nature, 1995, vol. 378, pp. 203–206.

Oliner, J.D., Kinzler, K.W., Meltzer, P.S., George, D.L., and Vogelstein, B., Amplification of a gene encoding a p53-associated protein in human sarcomas, Nature, 1992, vol. 358, pp. 80–83.

Pallante, P., Battista, S., Pierantoni, G.M., and Fusco, A., Deregulation of microRNA expression in thyroid neoplasias, Nat. Rev. Endocrinol., 2014, vol. 10, pp. 88–101.

Sarwar, M.R. and Saqib, A., Cancer prevalence, incidence and mortality rates in Pakistan in 2012, Cogent. Med., 2017, vol. 34, pp. 1–13.

Thrower, J.S., Hoffman, L., Rechsteiner, M., and Pickart, C.M., Recognition of the polyubiquitin proteolytic signal, EMBO J., 2000, vol. 19, pp. 94–102.

Ward, E.M., Jemal, A., and Chen, A., Increasing incidence of thyroid cancer: is diagnostic scrutiny the sole explanation?, Future Oncol., 2010, vol. 6, pp. 185–188.

Xing, M., Molecular pathogenesis and mechanisms of thyroid cancer, Nat. Rev. Cancer, 2013, vol. 13, pp. 184–199.

Yuan, Z., Yang, Z ., and Zheng, Q., Deregulation of microRNA expression in thyroid tumors, J. Zhejiang Univ. Sci. B, 2014, vol. 15, pp. 212–224.

Zhao, J., Blayney, A., Liu, X., Gandy, L., Jin, W., Yan, L., Ha, J.H., Canning, A.J., Connelly, M., Yang, C., and Liu, X., EGCG binds intrinsically disordered N-terminal domain of p53 and disrupts p53-MDM2 interaction, Nat. Commun., 2021, vol. 12, no. 1, pp. 1–1.